Neurizon Therapeutics Ltd.
- Biotech or pharma, therapeutic R&D
Neurizon is developing a small molecule mTOR inhibitor (NUZ-001) for the treatment of neurodegenreative diseases, including a clinical stage program in Amyotrophic Lateral Sclerosis and pre-clinical programs in Alzheimer's Disease and Parkinson's Disease based on in vitro data that demonstrates NUZ-001 inhibits TDP-43 aggregation n neuronal cells. Following a successful Phase I clinical trial and Open Label Extension Study in Australia, NUZ-001 has been accepted onto the prestigious HEALEY ALS Platform for a Phase II/III clinical trial in the USA. Enrolment is expected to begin at the end of 2025.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}